Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ENX-102 · 1 trial · 1 indication
• Incidence and severity of treatment-emergent AEs (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo |
| ENX-102 low-dose | EXPERIMENTAL | ENX-102 |
| ENX-102 mid-dose | EXPERIMENTAL | ENX-102 |
| ENX-102 high-dose | EXPERIMENTAL | ENX-102 |
| Name | Type | Description |
|---|---|---|
| ENX-102 | DRUG | Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period |
| Placebo | DRUG | Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period |
Key Inclusion Criteria: * Male or female, inclusive of any gender identity, aged 18 to 65 years, inclusive * Diagnosed with GAD according to the DSM-V, confirmed by MINI * Experiencing clinically significant generalized anxiety as measured by HAM-A score ≥18 and at least moderately severe core symp...
ENX-102 is an investigational small molecule being developed for the treatment of Generalized Anxiety Disorder (GAD). It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied for its potential to address symptoms of anxiety in adult patients.
ENX-102 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for Generalized Anxiety Disorder.
ENX-102 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. A Phase 2 clinical trial has been completed to evaluate the drug's safety and dose-response in patients with Generalized Anxiety Disorder.
ENX-102 has one completed Phase 2 clinical trial registered as NCT06653296, titled "A Dose-Response Safety Study of ENX-102 in Patients With GAD." This randomized, double-blind, placebo-controlled study enrolled 38 adult participants in the United Kingdom and evaluated the drug's safety in Generalized Anxiety Disorder.
No, ENX-102 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Generalized Anxiety Disorder. The drug has completed a Phase 2 safety study, but it has not yet received regulatory approval and remains under clinical investigation.